AD

Award Number: DAMD17-01-1-0481

TITLE: The Structural Basis for the Role of CHK as a Tumor Suppressor Protein in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Jerome E. Groopman, M.D. Gordon D. Webster, Ph.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center Boston, Massachusetts 02215-5399

REPORT DATE: May 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030313 122

REPORT DOCUMENTATION PAGE			Form Approved OMB No 074-0188	
Public reporting burden for this collection of inform the data needed, and completing and reviewing thi reducing this burden to Washington Headquarters	ation is estimated to average 1 hour per responses s collection of information. Send comments rega Services, Directorate for Information Operations	e, including the time for reviewing in Irding this burden estimate or any of and Reports, 1215 Jefferson Davis I	structions, searching ex her aspect of this collec dighway, Suite 1204, Ar	isting data sources, gathering and maintain tion of information, including suggestions for lington, VA 22202-4302, and to the Office
Management and Budget, Paperwork Reduction P 1. AGENCY USE ONLY (Leave blank	roject (0704-0188), Washington, DC 20503	3. REPORT TYPE AND	DATES COVERED	
4. TITLE AND SUBTITLE	May 2002	Amnual (1 May	5. FUNDING NUMBERS	
The Structural Basis for the Role Breast Cancer	of CHK as a Tumor Suppressor	Protein in Human	DAMD17-01	-1-0481
6. AUTHOR(S) Jerome E. Groopman, M.I Gordon D. Webster, Ph.D.).			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)			8. PERFORMING ORGANIZATION	
Beth Israel Deacone Boston, Massachuset E-Mail jgroopma@caregroup.harv	ess Medical Center ts 02215-5399 ard.edu		REPORT NO	MDER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				
12a. DISTRIBUTION / AVAILABILITY Approved for Public Re	STATEMENT lease; Distribution Un	limited		12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Wol	ds)			
The goal of this project crystals of the closed diffraction studies from structure. Our research tail of the active Her-	ct is to determine how and purified, recombi om which we can determ ch will focus upon the 2/neu receptor.	CHK functions a nant CHK SH2 dom ine its precise, structural deta	t the mole ain will b three-dim ils of how	cular level, e obtained for X-ra ensional, molecular CHK recognizes the
14. SUBJECT TERMS CHK, breast cancer, He:	c-2/new receptor			15. NUMBER OF PAGES 4 16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSII OF ABSTRACT Unclassif	FICATION	20. LIMITATION OF ABSTRA
			-	

Table of Contents

Cover	1
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Reportable Outcomes	4
Appendices	4

Introduction:

We have made considerable progress towards the goals of the project. This work set the stage for developing structural information that may assist in designing novel therapeutics against breast cancer based on mimicking the activity of CHK as an inhibitor of Her2/neu pathway.

Body:

Experiments were conducted as described in the original proposal. In addition, advances were made using different expression systems to obtain purified CHK proteins for structural analysis.

Key Research Accomplishments:

Over the past year, we successfully expressed different truncated variants of SH2 domain of human CHK from the pGEX vector in E. coli. Each of the variants was purified by affinity chromatography and subjected to preliminary crystallization trials using hampton screens. One of the variants yielded preliminary crystals which diffracted to a resolution of 2.5 Å and extensive optimization yielded crystals which diffracted to a resolution of 1.8 Å. The crystal structure of the SH2 domain of CHK was solved at a resolution of 2.5 Å by molecular replacement method and deposited in the data bank (PDB ID: 1JWO).

Unfortunately, attempts to co-crystallize the SH2 domain with several synthetic peptide analogs of HER2/neu receptor did not yield diffractable crystals.

The crystal structure of the SH2 domain was modeled with a peptide using energy minimization. In addition, the kinase domain of CHK was expressed and affinity purified to ~1mg per liter culture from Pichia pastoris. To date, we are unable to express full length and some truncated variants of CHK from Pichia pastoris.

The SH2 domains of CHK and Csk share ~80% sequence homology. Comparison of the structure of SH2 domain of CHK with that of Csk could yield useful information with regards to the interaction with the HER2/neu receptor. To that end, we cloned and expressed from the pGEX vector, in E.coli, the SH2 domains of CHK.

Thus, we have made considerable progress towards our goal but have not yet achieved the ultimate objective of a co-crystal of CHK with the Her2/neu receptor. Our efforts continue using parallel strategies to overcome the pitfalls we face in certain expression systems and feel that these new avenues may soon be fruitful.

Reportable Outcomes: We plan to report the methods for crystallization of CHK SH2 domain and have deposited in the databank the crystal structure of the CHK SH2 domain with a resolution of 2.5 Å.

Conclusions:

CHK is an important regulator of breast cancer growth and spread and appears to act by interaction with the Her2/neu receptor. Our work has advanced to the field in obtaining some structural information on CHK and set the stage for further studies that could lead to novel therapies against breast cancer.

References: none

Appendices: none